Treatment of influenza with neuraminidase inhibitors
Treatment of influenza with neuraminidase inhibitors
PURPOSE OF REVIEW:
Seasonal and pandemic influenza are major causes of morbidity and mortality globally. Neuraminidase inhibitors (NAIs) are the only class of antiviral agent recommended for the treatment of currently circulating strains of influenza. There has previously been controversy over the level of evidence for patient benefit with NAIs. We review here the current evidence base for the clinical impact of treatment of influenza with NAIs.
RECENT FINDINGS:
Meta-analysis of pharma-sponsored studies (including previously unpublished data) shows that NAIs reduce the duration of illness in influenza-infected patients, and suggest a possible reduction in the rate of complications and hospitalization. Meta-analysis of observational studies examining oseltamivir use during the H1N1 2009 pandemic, suggest a reduction in hospitalization rate in community-dwelling patients and a reduction in mortality in hospitalized adults treated with NAIs. Current NAI use in the community and hospitals varies widely but in general they are underutilized.
SUMMARY:
Although there has been controversy over the level of evidence for patient benefit, a growing body of evidence suggests that treatment of influenza with NAIs is associated with improved outcomes for both patients in the community and more severely unwell patients in hospital. Clinical outcomes are optimal with earlier use and strategies to improve early widespread NAI utilization are needed.
514-519
Beard, Kate
85604fec-3541-48cb-9abf-a76c2a32c3f1
Brendish, Nathan
a8a4189e-01eb-4ab3-933e-a24cd188a4d7
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f
17 October 2018
Beard, Kate
85604fec-3541-48cb-9abf-a76c2a32c3f1
Brendish, Nathan
a8a4189e-01eb-4ab3-933e-a24cd188a4d7
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f
Beard, Kate, Brendish, Nathan and Clark, Tristan
(2018)
Treatment of influenza with neuraminidase inhibitors.
Current Opinion in Infectious Diseases, 31 (6), .
(doi:10.1097/QCO.0000000000000496).
Abstract
PURPOSE OF REVIEW:
Seasonal and pandemic influenza are major causes of morbidity and mortality globally. Neuraminidase inhibitors (NAIs) are the only class of antiviral agent recommended for the treatment of currently circulating strains of influenza. There has previously been controversy over the level of evidence for patient benefit with NAIs. We review here the current evidence base for the clinical impact of treatment of influenza with NAIs.
RECENT FINDINGS:
Meta-analysis of pharma-sponsored studies (including previously unpublished data) shows that NAIs reduce the duration of illness in influenza-infected patients, and suggest a possible reduction in the rate of complications and hospitalization. Meta-analysis of observational studies examining oseltamivir use during the H1N1 2009 pandemic, suggest a reduction in hospitalization rate in community-dwelling patients and a reduction in mortality in hospitalized adults treated with NAIs. Current NAI use in the community and hospitals varies widely but in general they are underutilized.
SUMMARY:
Although there has been controversy over the level of evidence for patient benefit, a growing body of evidence suggests that treatment of influenza with NAIs is associated with improved outcomes for both patients in the community and more severely unwell patients in hospital. Clinical outcomes are optimal with earlier use and strategies to improve early widespread NAI utilization are needed.
Text
COID NAIs TWC
- Accepted Manuscript
More information
Accepted/In Press date: 19 September 2018
e-pub ahead of print date: 12 October 2018
Published date: 17 October 2018
Identifiers
Local EPrints ID: 425435
URI: http://eprints.soton.ac.uk/id/eprint/425435
ISSN: 0951-7375
PURE UUID: 3e65dcc4-19ae-44a8-b545-53fcba03cb81
Catalogue record
Date deposited: 19 Oct 2018 16:30
Last modified: 06 Nov 2024 05:03
Export record
Altmetrics
Contributors
Author:
Kate Beard
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics